Somewhat Positive News Coverage Somewhat Unlikely to Impact Acceleron Pharma (XLRN) Share Price
News stories about Acceleron Pharma (NASDAQ:XLRN) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a news impact score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.8784802707325 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Acceleron Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Credit Suisse Group set a $35.00 target price on shares of Acceleron Pharma and gave the stock a “buy” rating in a research report on Saturday, August 5th. BidaskClub raised shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 6th. Citigroup Inc. boosted their target price on shares of Acceleron Pharma to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $40.00 target price on shares of Acceleron Pharma in a research report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Acceleron Pharma has an average rating of “Buy” and an average price target of $41.21.
Acceleron Pharma (XLRN) traded up 0.66% during mid-day trading on Wednesday, hitting $36.75. 389,100 shares of the stock traded hands. The company has a 50 day moving average of $33.12 and a 200-day moving average of $29.61. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $41.69. The stock’s market cap is $1.42 billion.
Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.12. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.69 million. During the same period in the prior year, the business earned ($0.59) earnings per share. Acceleron Pharma’s quarterly revenue was down 3.1% on a year-over-year basis. Equities research analysts forecast that Acceleron Pharma will post ($2.73) earnings per share for the current year.
In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 34,400 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $1,100,800.00. Following the sale, the chief financial officer now directly owns 80,950 shares of the company’s stock, valued at $2,590,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Matthew L. Sherman sold 16,000 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $512,000.00. Following the completion of the sale, the executive vice president now directly owns 112,400 shares in the company, valued at $3,596,800. The disclosure for this sale can be found here. Insiders sold 64,402 shares of company stock worth $2,105,416 over the last ninety days. 3.90% of the stock is owned by corporate insiders.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.